IBRX Investors: Join the Class Action Against ImmunityBio, Inc. Today

IBRX Investors Have an Opportunity to Lead ImmunityBio Class Action

In a recent announcement, the Rosen Law Firm, a prominent name in investor rights litigation, has called attention to the ongoing class action against ImmunityBio, Inc. (NASDAQ: IBRX). This lawsuit arises from claims of securities fraud affecting investors who purchased ImmunityBio stock between January 19, 2026, and March 24, 2026.

Why Should You Pay Attention?

The Rosen Law Firm has highlighted an important deadline: May 26, 2026, marks the last day for investors to apply to be the lead plaintiff in this case. If you bought ImmunityBio shares during the specified period, you may be eligible for compensation. Notably, there are no out-of-pocket fees attached to joining this class action, thanks to a contingency fee arrangement.

Next Steps for Investors

Interested individuals are encouraged to take immediate action. You can join the class action by visiting the Rosen Law website, where a submission form is available at: Rosen Legal Submission Form. Alternatively, you can reach out to Phillip Kim, Esq., via toll-free at 866-767-3653 or through email for more detailed insights regarding the proceeding.

The essence of this lawsuit revolves around significant misstatements made by ImmunityBio during the Class Period. The claims assert that Patrick Soon-Shiong, a key defendant, exaggerated the potential of a product named Anktiva, leading to widespread misinformation about the company's operations and future outlook. As the truth surfaced, investors faced substantial losses.

The Rosen Law Firm's Credibility

Navigating legal representation in such scenarios can be daunting, and the decision on whom to trust is critical. The Rosen Law Firm has established a robust reputation within the investor community. The firm specializes in securities class actions, demonstrating a history of successful outcomes — including recovering millions for investors in previous settlements and receiving accolades for their case-handling capabilities.

Importantly, the firm was recognized as having secured the largest securities class action settlement against a Chinese company and has consistently ranked highly in terms of settlements achieved over the years. Their client-focused approach prioritizes the need for experienced counsel and aims to empower investors in navigating complex legal landscapes.

What is Required to Participate?

If you decide to be part of this class action, it’s crucial to note the necessity of submitting your motion to the Court by the deadline of May 26, 2026. Being a lead plaintiff means actively participating as a representative in directing the litigation on behalf of all class members. However, it’s important to clarify that until a class is certified, there’s no legal representation unless you choose to formally retain an attorney. If you prefer not to engage at this moment, you can still remain an absent class member while preserving your potential claim.

Stay Updated

As the situation unfolds, staying updated is vital. The Rosen Law Firm provides current updates through various social media platforms, including LinkedIn, Twitter, and Facebook. This ensures that investors remain informed regarding any developments in the case and can make timely decisions on their involvement.

In conclusion, if you are an IBRX investor during the specified period, consider consulting the Rosen Law Firm to explore your options. This is a significant opportunity to not only pursue justice for any potential losses suffered but also to ensure that corporate accountability is upheld in the financial marketplace.

For more information, you can contact the firm's offices at:

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Email: [email protected]